Incyte Corporation (INCY)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
88.98-0.29 (-0.32%)
At close: 4:00 PM EDT
People also watch:
VRTXBMRNALXNMYGNREGN
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open88.39
Prev Close89.27
Bid60.00 x 100
Ask0.00 x
Day's Range88.39 - 91.24
52wk Range55.00 - 131.33
1y Target EstN/A
Market Cap16.73B
P/E Ratio (ttm)241.79
Beta1.19
Volume1,240,442
Avg Vol (3m)1,145,055
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Incyte Corp. – Value Analysis (NASDAQ:INCY) : September 21, 2016
    Capital Cube5 days ago

    Incyte Corp. – Value Analysis (NASDAQ:INCY) : September 21, 2016

    Categories: Fundamental Analysis Yahoo Finance Click here to see latest analysis Capitalcube gives Incyte Corp. a score of 69. Our analysis is based on comparing Incyte Corp. with the following peers – Celgene Corporation, Amgen Inc., Ligand Pharmaceuticals Incorporated, Ionis Pharmaceuticals, Inc., Eli Lilly and Company, Pfizer Inc., Geron Corporation, Novartis AG Sponsored ADR, Ardelyx, Inc. and AVEO Pharmaceuticals, Inc. ... Read more (Read more...)

  • Incyte Corp. breached its 50 day moving average in a Bullish Manner : INCY-US : September 20, 2016
    Capital Cube6 days ago

    Incyte Corp. breached its 50 day moving average in a Bullish Manner : INCY-US : September 20, 2016

    Categories: ETFs Yahoo Finance Click here to see latest analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Incyte Corp.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average ... Read more (Read more...)

  • Forbes7 days ago

    After Losing Medivation, Who Is Gilead Going After Next?

    Gilead Sciences has been consistently pressured by analysts to make an acquisition over the past 18 months. The company has been incredibly frugal, stockpiling cash, and avoiding overpaying in an acquisition just to make the analysts happy. They made a bid to purchase Medivation, but lost out to Pfizer. Todd Hagopian says that GILD’s performance the last 15 months (down 34% from it’s high), and it’s huge stockpile of cash (recently bolstered through a $5 billion debt offering), make it unlikely the company will be able to hold off from making a strategic acquisition much longer.